Egalet Corporation (Nasdaq: EGLT) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, March 29, 2017 (GLOBE NEWSWIRE) --

What:

Egalet Corporation (Nasdaq:EGLT), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Robert Radie, President and CEO, will ring the Closing Bell. 

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Thursday, March 30, 2017 – 3:45 p.m. to 4:00 p.m. ET   

Egalet Contact:

E. Blair Clark-Schoeb

Senior Vice President, Communications

bcs@egalet.com

917-432-9275

Nasdaq MarketSite:

Emily Pan

(646) 441-5120

emily.pan@nasdaq.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:

http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:

http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:

http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:

http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:

http://nasdaq.tumblr.com/

Webcast:

A live stream of the Nasdaq Closing Bell will be available at:

https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.           

About Egalet 

Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO™ ER (morphine sulfate) extended-release tablets for oral use only –CII, developed using Egalet's proprietary Guardian™ Technology, OXAYDO® (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX® (ketorolac tromethamine) Nasal Spray. Using Guardian Technology, Egalet is developing a pipeline of clinical-stage, product candidates including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For full prescribing information on ARYMO ER, including the boxed warning and medication guide, please visit arymoer.com. For full prescribing information on SPRIX, including the boxed warning and medication guide, please visit sprix.com. For full prescribing information on OXAYDO, including the boxed warning and medication guide, please visit oxaydo.com. For additional information on Egalet, please visit egalet.com.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 85 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,800 listed companies with a market value of $10.1 trillion and nearly 18,000 corporate clients. To learn more, visit: business.nasdaq.com.

-NDAQA-

In This Story

NDAQ